# US 7,608,640 B2 · Glycine betaine and its use > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,608,640 B2 - Document ID: US7608640B2 - Status: Granted - Kind: B2 - Application number: 10/635,048 - Filed: 2003-08-04 - Published: 2004-02-19 - Granted: 2009-10-27 - Earliest claimed: 2001-12-21 - Inventors: Jallal Messadek - Web page: https://patentgrep.com/patent/US7608640B2 ## CPC - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation. ## Claims ### Claim 1 A controlled release pharmaceutical system suitable for delivering after administration in a time-controlled manner to the bloodstream of a mammal comprising an effective amount of an active compound selected from the group consisting of a compound of the formula (CH3)3N+(CH2)nCOO−, with n equal to 1, pharmaceutically acceptable salts thereof, and mixtures thereof. ### Claim 2 (depends on 1) The system of claim 1, said system being selected from the group consisting of oral control led release preparations, oral controlled release devices, transdermal controlled release preparations, transdermal controlled release devices, and combinations thereof. ### Claim 3 (depends on 1) The system of claim 1 wherein said system comprises at least one electronic element selected from the group consisting of an electronic device and chip, said at least one element operable for controlling at least the releasing of the active compound. ### Claim 4 (depends on 1) The system of claim 1, said system controlling delivery of said compound for at least about 120 minutes. ### Claim 5 A controlled release pharmaceutical system for achieving a goal selected from the group consisting of treating a condition, reducing the incidence of a condition, and reducing the severity of a condition, whereby said condition is selected from the group consisting of blood flow disturbances, thrombosis, thromboembolic disorders, and combinations thereof, said system being adapted for releasing in a time controlled manner for at least 120 minutes, after administration, a therapeutically effective amount of an active compound selected from the group consisting of a compound of the formula (CH3)3N+(CH2)nCOO−, with n equal to 1, pharmaceutically acceptable salts of said compound, and mixtures thereof. ### Claim 6 (depends on 5) The system of claim 5, said system being an oral controlled release pharmaceutical system. ### Claim 7 (depends on 5) The system of claim 5 wherein said system comprises at least one electronic element selected from the group consisting of an electronic device and chip, said element being operable for controlling the release of the active compound. ### Claim 8 (depends on 5) The system of claim 5, wherein the system is adapted for controlling the release of said active compound for at least for 180 minutes. ### Claim 9 (depends on 5) The system of claim 5, wherein the system is adapted for controlling the release of said active compound for at least for 240 minutes. ### Claim 10 (depends on 5) The system of claim 5, wherein the system is adapted for controlling the release of said active compound for at least for 360 minutes. ### Claim 11 A controlled release pharmaceutical system tor releasing an effective therapeutic amount of a compound selected from the group consisting of a compound of the formula (CH3)3N+(CH2)nCOO−, with n equal to 1, pharmaceutically acceptable salts thereof, and mixtures thereof, wherein said system is adapted for controlling for at least 120 minutes the release of an effective amount of a compound of glycine betaine, pharmaceutically acceptable salts thereof, and mixtures thereof. ### Claim 12 (depends on 11) The system of claim 11, in which the system is adapted for controlling at least for 180 minutes the release of an effective amount of a compound selected from the group consisting of a compound of formula (CH3)3N+(CH2)n COO− with n being an integer of 1, pharmaceutically acceptable salts thereof, and mixtures thereof. ### Claim 13 (depends on 11) The system of claim 11, in which the system is adapted for controlling the release of an effective amount of a compound selected from the group consisting of a compound of formula (CH3)3N+(CH2)n COO− with n being an integer of 1, pharmaceutically acceptable salts thereof, and mixtures thereof for a time period of from about 240 minutes to 2160 minutes. ### Claim 14 (depends on 11) The system of claim 11 wherein said system comprises at least one electronic element selected from the group consisting of an electronic device and chip, said element being operable for controlling the release of the active compound. ### Claim 15 A controlled release pharmaceutical system for achieving a goal selected from the group consisting of treating a condition, reducing the incidence of a condition, and reducing the severity of a condition, whereby said condition is selected from the group consisting of blood flaw disturbances, thrombosis, thromboembolic disorders, and combinations thereof, said system being adapted for releasing in a time controlled manner for at least 2160 minutes, after administration, a therapeutically effective amount at an active compound selected from the group consisting of a compound of the formula (CH3)3N+(CH2)nCOO−, with n equal to 1, pharmaceutically acceptable salts thereof, and mixtures thereof.